Myriad Study Finds High Prevalence of Mutations in the PMS2 Gene
March 29 2012 - 04:15PM
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a
presentation entitled, "Representation of PMS2 mutations in
patients seeking genetic testing for Lynch syndrome," was presented
at the 2012 American College of Medical Genetics and Genomics
(ACMG) Annual Clinical Genetics Meeting. The study found cancer
causing mutations in the PMS2 gene in 14 percent of patients with
personal and family histories suggestive of Lynch syndrome, a
hereditary form of colon cancer. The study concluded that
comprehensive diagnostic testing for Lynch syndrome should include
the PMS2 gene.
"These findings confirm the importance of analyzing the PMS2
gene when assessing a patient's Lynch syndrome status," said Mark
Capone, President of Myriad Genetic Laboratories. "Myriad offers an
analysis of the PMS2 gene and is working with physicians and
patients to ensure they are educated on the importance of this gene
in Lynch syndrome."
Researchers at Myriad analyzed the prevalence of genetic
mutations using the COLARIS® test in 327 patients to confirm the
importance of testing for mutations in the PMS2 gene. Cancer
causing mutations were also found in the MSH2, MLH1, and MSH6
genes. Approximately 38 percent of patients were found to have
a mutation in the MSH2 gene, 30 percent in the MLH1 gene, 18
percent in the MSH6 gene and 14 percent of mutations were found in
the PMS2 gene.
This study demonstrates the importance of the analyzing the PMS2
gene to fully comprehend a patient's Lynch syndrome
status.
About COLARIS
COLARIS is a genetic test that can identify genetic mutations in
the MLH1, MSH2, MSH6, and PMS2 genes. This test is designed to
assess a person's risk of developing colorectal and endometrial
cancer as well as other hereditary cancers associated with Lynch
syndrome. A patient who tests positive with the COLARIS test has up
to an 82% chance of developing colorectal cancer and up to a 71%
chance of developing endometrial cancer.
About Myriad Genetics
Myriad Genetics, Inc. is a leading molecular diagnostic company
dedicated to making a difference in patient's lives through the
discovery and commercialization of transformative tests to assess a
person's risk of developing disease, guide treatment decisions and
assess risk of disease progression and recurrence. Myriad's
portfolio of nine molecular diagnostic tests are based on an
understanding of the role genes play in human disease and were
developed with a focus on improving an individual's decision making
process for monitoring and treating disease. With fiscal year 2011
annual revenue of over $400 million and more than 1,000 employees,
Myriad is working on strategic directives, including new product
introductions, companion diagnostics, and international expansion,
to take advantage of significant growth opportunities. For
more information on how Myriad is making a difference, please visit
the Company's website: www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP,
Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are
trademarks or registered trademarks of Myriad Genetics, Inc. in the
United States and foreign countries. MYGN-G
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, the importance of analyzing the PMS2 gene when assessing a
patient's Lynch syndrome status; Myriad's work with physicians and
patients to ensure they are educated on the importance of this gene
in Lynch syndrome; the increase in sensitivity, as a result of the
PMS2 gene, being clearly meaningful; the demonstrated importance of
analyzing the PMS2 gene to fully comprehend a patient's Lynch
syndrome status; and the Company's strategic directives under the
caption "About Myriad Genetics". These "forward-looking statements"
are based on management's current expectations of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by forward-looking statements. These risks
and uncertainties include, but are not limited to: the risk that
sales and profit margins of our existing molecular diagnostic tests
and companion diagnostic services may decline or will not continue
to increase at historical rates; the risk that we may be unable to
expand into new markets outside of the United States; the risk that
we may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and companion diagnostic
services in a timely manner, or at all; the risk that we may not
successfully develop new markets for our molecular diagnostic tests
and companion diagnostic services, including our ability to
successfully generate revenue outside the United States; the risk
that licenses to the technology underlying our molecular diagnostic
tests and companion diagnostic services and any future products are
terminated or cannot be maintained on satisfactory terms; risks
related to delays or other problems with manufacturing our products
or operating our laboratory testing facilities; risks related to
public concern over genetic testing in general or our tests in
particular; risks related to regulatory requirements or enforcement
in the United States and foreign countries and changes in the
structure of healthcare payment systems; risks related to our
ability to obtain new corporate collaborations and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we acquire; the
development of competing tests and services; the risk that we or
our licensors may be unable to protect the proprietary technologies
underlying our tests; the risk of patent-infringement and
invalidity claims or challenges of our patents; risks of new,
changing and competitive technologies and regulations in the United
States and internationally; and other factors discussed under the
heading "Risk Factors" contained in Item 1A in our most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission, as well as any updates to those risk factors filed from
time to time in our Quarterly Reports on Form 10-Q or Current
Reports on Form 8-K. All information in this press release is as of
the date of the release, and Myriad undertakes no duty to update
this information unless required by law.
CONTACT: Rebecca Chambers
Director, Investor Relations and Corporate Communications
(801) 584-1143
rchambers@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2023 to Mar 2024